Literature DB >> 2145907

Validation of clinical predictive value of in vitro colorimetric chemosensitivity assay in head and neck cancer.

W Schroyens1, E Tueni, P Dodion, R Bodecker, F Stoessel, J Klastersky.   

Abstract

For chemosensitivity testing, a rapid in vitro colorimetric method (MTT assay) was used. Eleven head and neck cancer cell lines were investigated to distinguish five known active agents from five compounds inactive in phase II studies. Evaluation of the reliability of the assay for assessing drug sensitivity in this tumor cell population was done by correlating the in vitro results with reported in vivo response data. Methotrexate and cisplatin (clinically active) and vindesine and doxorubicin (less active clinically) were recognized in vitro as active and correlated well with clinical experience. Bleomycin (clinically active) was ineffective against some cell lines. The in vitro findings for the clinically inactive drugs (deoxyazacytidine, lomustine, and carmustine) also corresponded. Amsacrine and etoposide, contrary to clinical experience, showed activity in vitro. Further comparison of MTT assay results with clinical data is warranted and essential before its use in large-scale drug screening studies.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2145907     DOI: 10.1016/0277-5379(90)90165-p

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  10 in total

1.  Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma.

Authors:  W Voigt; T Kegel; M Weiss; T Mueller; H Simon; H J Schmoll
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

Review 2.  [Pharmacological characterization of head and neck cancer in ex-vivo tests].

Authors:  G Wichmann; A Dietz
Journal:  HNO       Date:  2011-09       Impact factor: 1.284

Review 3.  Novel treatments for anaplastic thyroid carcinoma.

Authors:  Silvia Martina Ferrari; Giusy Elia; Francesca Ragusa; Ilaria Ruffilli; Concettina La Motta; Sabrina Rosaria Paparo; Armando Patrizio; Roberto Vita; Salvatore Benvenga; Gabriele Materazzi; Poupak Fallahi; Alessandro Antonelli
Journal:  Gland Surg       Date:  2020-01

4.  Assay-based response evaluation in head and neck oncology: requirements for better decision making.

Authors:  Andreas Dietz; Andreas Boehm; Iris-Susanne Horn; Pierre Kruber; Ingo Bechmann; Wojciech Golusinski; Dietger Niederwieser; Ralph Dollner; Torsten W Remmerbach; Christian Wittekind; Stephan Dietzsch; Guido Hildebrandt; Gunnar Wichmann
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-01-06       Impact factor: 2.503

5.  New targeted molecular therapies for dedifferentiated thyroid cancer.

Authors:  Alessandro Antonelli; Clodoveo Ferri; Silvia Martina Ferrari; Marco Sebastiani; Michele Colaci; Ilaria Ruffilli; Poupak Fallahi
Journal:  J Oncol       Date:  2010-06-06       Impact factor: 4.375

6.  Promising cytotoxic activity profile of fermented wheat germ extract (Avemar®) in human cancer cell lines.

Authors:  Thomas Mueller; Karin Jordan; Wieland Voigt
Journal:  J Exp Clin Cancer Res       Date:  2011-04-16

Review 7.  Selective use of vandetanib in the treatment of thyroid cancer.

Authors:  Poupak Fallahi; Flavia Di Bari; Silvia Martina Ferrari; Roberto Spisni; Gabriele Materazzi; Paolo Miccoli; Salvatore Benvenga; Alessandro Antonelli
Journal:  Drug Des Devel Ther       Date:  2015-07-03       Impact factor: 4.162

8.  Personalization of targeted therapy in advanced thyroid cancer.

Authors:  Poupak Fallahi; Silvia Martina Ferrari; Valeria Mazzi; Roberto Vita; Salvatore Benvenga; Alessandro Antonelli
Journal:  Curr Genomics       Date:  2014-06       Impact factor: 2.236

Review 9.  New therapies for dedifferentiated papillary thyroid cancer.

Authors:  Poupak Fallahi; Valeria Mazzi; Roberto Vita; Silvia Martina Ferrari; Gabriele Materazzi; David Galleri; Salvatore Benvenga; Paolo Miccoli; Alessandro Antonelli
Journal:  Int J Mol Sci       Date:  2015-03-17       Impact factor: 5.923

10.  Chemosensitivity testing of fresh human gastric cancer with highly purified tumour cells using the MTT assay.

Authors:  H Yamaue; H Tanimura; K Noguchi; T Hotta; M Tani; T Tsunoda; M Iwahashi; M Tamai; S Iwakura
Journal:  Br J Cancer       Date:  1992-11       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.